NovaBridge Biosciences (NBP) EBT Margin (2019 - 2023)
NovaBridge Biosciences (NBP) posted quarterly EBT Margin of 738200.0% for Q4 2023, down 28185.25% quarter-over-quarter from 2609.84% in Q3 2023.
Powered by 
Analysis
NovaBridge Biosciences (NBP) EBT Margin (2019 - 2023) Analysis & Trends
NovaBridge Biosciences (NBP) has reported EBT Margin for 3 consecutive years, with 738200.0% the latest figure, recorded in Q4 2023.
- In Q4 2023, EBT Margin changed N/A year-over-year to 738200.0%; the TTM figure through Dec 2023 stood at 4361.77% (changed N/A YoY), while the FY2023 annual figure was 13009.02%, down 391166.0% from the prior year.
- EBT Margin retreated to 738200.0% in Q4 2023 per NBP's latest filing, from 2609.84% in the prior quarter.
- Across five years, EBT Margin topped out at 5920.12% in Q4 2020 and bottomed at 738200.0% in Q4 2023.
- Historically, EBT Margin has averaged 150772.42% across 3 years, with a median of 2609.84% in 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -738,200.00% |
| Sep 30, 2023 | -2,609.84% |
| Jun 30, 2023 | -17,332.08% |
| Dec 31, 2020 | 68.75% |
| Sep 30, 2019 | -1,640.29% |